title: [The anti-viral activity of the complex glycyrrhizic acid-alpha-glutamyl-tryptophan against experimental lethal influenza infection in white mice caused by oseltamivir-resistant strain of the virus].
abstract: Influenza virus is a leading causing factor of infectious respiratory human pathology. The ability to implement the antigenic drift and development of drug resistance makes it important to develop novel anti-influenza drugs of wide spectrum of activity. In this work, we present the results of the study of the activity of a combination of glycyrrhizic acid with dipeptide alpha-glutamyl-tryptophan against oseltamivir-reistant strain of the virus Al Vladivostok/2/09 (H1 N1) on the model of lethal influenza infection in white mice. Application of Orvilax was shown to decrease the specific mortality of animals (index of protection 39-67% depending on the dose of the virus and drugs combination), to increase the mean day of death to 3.7-5.0 days and decrease the infectious titer of the virus in lung tissue to 1.3 Ig EID50/20 mg. The corresponding figures for the reference compound Tamiflu were 8-11%, 0.5-1.5 days, and 0.6 Ig EID50/20 mg. The use of Orvilax also led to reliable increase of the titers of interferon in the blood from 30.4 to 56.5 ME/mL. The results obtained allow the drug to be considered as a promising anti-influenza remedy that is active against the drug-resistant virus strains.
authors.forename: V S
authors.initials: VS
authors.lastname: Smirnov
authors.forename: A V
authors.initials: AV
authors.lastname: Garshinina
authors.forename: V M
authors.initials: VM
authors.lastname: Guseva
authors.forename: N A
authors.initials: NA
authors.lastname: Kalinina
authors.forename: A A
authors.initials: AA
authors.lastname: Shtro
authors.forename: S V
authors.initials: SV
authors.lastname: Beliaevskaia
authors.forename: V B
authors.initials: VB
authors.lastname: Anikin
authors.forename: V V
authors.initials: VV
authors.lastname: Zarubaev
mesh_terms: D000818:Animals; D021461:Animals, Outbred Strains; D000998:Antiviral Agents / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology*; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D019695:Glycyrrhizic Acid / Q000494:pharmacology*; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D007372:Interferons / Q000096:biosynthesis / Q000097:blood; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000821:virology; D053139:Oseltamivir / Q000494:pharmacology; D016019:Survival Analysis; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004151:Dipeptides; D004338:Drug Combinations; D053139:Oseltamivir; C057081:alpha-glutamyltryptophan; D019695:Glycyrrhizic Acid; D007372:Interferons